WO2000044360A3 - Drugs for treatment of psychiatric and brain disorders - Google Patents

Drugs for treatment of psychiatric and brain disorders Download PDF

Info

Publication number
WO2000044360A3
WO2000044360A3 PCT/GB2000/000137 GB0000137W WO0044360A3 WO 2000044360 A3 WO2000044360 A3 WO 2000044360A3 GB 0000137 W GB0000137 W GB 0000137W WO 0044360 A3 WO0044360 A3 WO 0044360A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
disease
psychiatric
compounds
metabolised
Prior art date
Application number
PCT/GB2000/000137
Other languages
French (fr)
Other versions
WO2000044360A2 (en
Inventor
David Frederick Horrobin
Original Assignee
Laxdale Ltd
Horrobin David F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laxdale Ltd, Horrobin David F filed Critical Laxdale Ltd
Priority to AU30638/00A priority Critical patent/AU3063800A/en
Publication of WO2000044360A2 publication Critical patent/WO2000044360A2/en
Publication of WO2000044360A3 publication Critical patent/WO2000044360A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pharmaceutical preparations which comprise compounds which can be metabolised by FACL enzymes are disclosed. Those compounds metabolised by FACL-4 to Coenzyme A derivatives are preferred. Highly unsaturated fatty acids (HUFAs) and their derivatives are suitable such compounds. The most preferred compound is eicosapentaenoic acid. The psychiatric disorders to be treated are schizophrenia, schizo-affective disorders, mania, depression, bipolar disorders, ADHD, anxiety and panic attacks, social phobias, Alzheimer's disease and other dementias, epilepsy, Parkinson's disease, stroke transient ischemic attack, multiple sclerose, Huntington's disease, and other neurodegenerative disorders.
PCT/GB2000/000137 1999-01-27 2000-01-20 Drugs for treatment of psychiatric and brain disorders WO2000044360A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU30638/00A AU3063800A (en) 1999-01-27 2000-01-20 Drugs for treatment of psychiatric and brain disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9901808.7A GB9901808D0 (en) 1999-01-27 1999-01-27 Drugs for treatment of psychiatric and brain disorders
GB9901808.7 1999-01-27

Publications (2)

Publication Number Publication Date
WO2000044360A2 WO2000044360A2 (en) 2000-08-03
WO2000044360A3 true WO2000044360A3 (en) 2000-11-30

Family

ID=10846602

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/000137 WO2000044360A2 (en) 1999-01-27 2000-01-20 Drugs for treatment of psychiatric and brain disorders

Country Status (3)

Country Link
AU (1) AU3063800A (en)
GB (1) GB9901808D0 (en)
WO (1) WO2000044360A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
WO2006105019A1 (en) * 2005-03-25 2006-10-05 Wisconsin Alumni Research Foundation Compounds and methods for treating seizure disorders

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0132089A1 (en) * 1983-07-14 1985-01-23 Scotia Holdings Plc Fatty acid compositions
US4678808A (en) * 1985-10-15 1987-07-07 Baxter Travenol Laboratories, Inc. Rapid acting intravenous emulsions of omega-3 fatty acid esters
EP0296751A1 (en) * 1987-06-24 1988-12-28 Efamol Holdings Plc Essential fatty acid compositions
EP0347056A1 (en) * 1988-06-10 1989-12-20 Scotia Holdings Plc Essential fatty acid compositions
EP0599576A1 (en) * 1992-11-26 1994-06-01 Scotia Holdings Plc Schizophrenia
EP0609001A2 (en) * 1993-01-27 1994-08-03 Scotia Holdings Plc Triglycerides
JPH06237734A (en) * 1991-11-06 1994-08-30 Sanwa Kagaku Kenkyusho Co Ltd Food composition for hypofunctional disease
JPH08143454A (en) * 1994-11-17 1996-06-04 Kanagawa Kagaku Kenkyusho:Kk Nerve growth factor production enhancer
WO1996021037A1 (en) * 1995-01-03 1996-07-11 Martek Biosciences Corporation Arachidonic acid and methods for the production and use thereof
WO1996031457A1 (en) * 1995-04-03 1996-10-10 Scotia Holdings Plc Triglycerides
WO1996040106A2 (en) * 1995-06-07 1996-12-19 Martek Biosciences Corporation Methods for controlling highly unsaturated fatty acid content in various tissues
WO1997004127A1 (en) * 1995-07-24 1997-02-06 Scotia Holdings Plc Diagnostic test for schizophrenia by analysing allelic variations in the cytosolic phospholipase a2 gene
WO1997039759A2 (en) * 1996-04-24 1997-10-30 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
WO1998016216A1 (en) * 1996-10-11 1998-04-23 Scotia Holdings Plc Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
WO1998048788A1 (en) * 1997-04-29 1998-11-05 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0132089A1 (en) * 1983-07-14 1985-01-23 Scotia Holdings Plc Fatty acid compositions
US4678808A (en) * 1985-10-15 1987-07-07 Baxter Travenol Laboratories, Inc. Rapid acting intravenous emulsions of omega-3 fatty acid esters
EP0296751A1 (en) * 1987-06-24 1988-12-28 Efamol Holdings Plc Essential fatty acid compositions
EP0347056A1 (en) * 1988-06-10 1989-12-20 Scotia Holdings Plc Essential fatty acid compositions
EP0454102A2 (en) * 1988-06-10 1991-10-30 Efamol Holdings Plc Essential fatty acid compositions
JPH06237734A (en) * 1991-11-06 1994-08-30 Sanwa Kagaku Kenkyusho Co Ltd Food composition for hypofunctional disease
EP0733360A2 (en) * 1992-11-26 1996-09-25 Scotia Holdings Plc Use of a combination of arachidonic acid and dosohexaenoic acid in the preparation of e medicament for treating cell membrane abnormalities due to low C20 or C22 essential fatty acids
EP0599576A1 (en) * 1992-11-26 1994-06-01 Scotia Holdings Plc Schizophrenia
EP0609001A2 (en) * 1993-01-27 1994-08-03 Scotia Holdings Plc Triglycerides
JPH08143454A (en) * 1994-11-17 1996-06-04 Kanagawa Kagaku Kenkyusho:Kk Nerve growth factor production enhancer
WO1996021037A1 (en) * 1995-01-03 1996-07-11 Martek Biosciences Corporation Arachidonic acid and methods for the production and use thereof
WO1996031457A1 (en) * 1995-04-03 1996-10-10 Scotia Holdings Plc Triglycerides
WO1996040106A2 (en) * 1995-06-07 1996-12-19 Martek Biosciences Corporation Methods for controlling highly unsaturated fatty acid content in various tissues
WO1997004127A1 (en) * 1995-07-24 1997-02-06 Scotia Holdings Plc Diagnostic test for schizophrenia by analysing allelic variations in the cytosolic phospholipase a2 gene
WO1997039759A2 (en) * 1996-04-24 1997-10-30 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
WO1998016216A1 (en) * 1996-10-11 1998-04-23 Scotia Holdings Plc Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
WO1998048788A1 (en) * 1997-04-29 1998-11-05 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ADAMS PETER B ET AL: "Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression.", LIPIDS, vol. 31, no. SUPPL., 1996, pages S157 - S161, XP000921353, ISSN: 0024-4201 *
ANNALS OF NUTRITION & METABOLISM, vol. 41, no. 4, 1997, pages 203 - 234, ISSN: 0250-6807 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1997, CALDER PHILIP C: "N-3 Polyunsaturated fatty acids and cytokine production in health and disease.", XP002146104, Database accession no. PREV199799817934 *
MELLOR JAN E ET AL: "Omega-3 fatty acid supplementation in schizophrenic patients.", HUMAN PSYCHOPHARMACOLOGY, vol. 11, no. 1, 1996, pages 39 - 46, XP000921351, ISSN: 0885-6222 *
MURPHY M G ET AL: "ACID COENZYME A LIGASE EC-6.2.1.3 IN BRAIN FATTY-ACID SPECIFICITY IN CELLULAR AND SUB CELLULAR FRACTIONS", JOURNAL OF NEUROCHEMISTRY, vol. 38, no. 3, 1982, pages 675 - 679, XP000921317, ISSN: 0022-3042 *
MURPHY M G ET AL: "LONG CHAIN FATTY-ACID COENZYME A LIGASE EC-6.2.1.3 IN RAT BRAIN IN-VITRO A COMPARISON OF ACTIVITIES WITH OLEIC-ACID AND CIS VACCENIC-ACID", JOURNAL OF NEUROCHEMISTRY, vol. 34, no. 2, 1980, pages 367 - 373, XP000921352, ISSN: 0022-3042 *
PATENT ABSTRACTS OF JAPAN vol. 018, no. 619 (C - 1278) 25 November 1994 (1994-11-25) *
PATENT ABSTRACTS OF JAPAN vol. 1996, no. 10 31 October 1996 (1996-10-31) *
PEET, MALCOLM ET AL: "n-3 polyunsaturated fatty acids in the treatment of schizophrenia", ESSENT. FATTY ACIDS EICOSANOIDS, INVITED PAP. INT. CONGR., 4TH (1998), MEETING DATE 1997, 354-357. EDITOR(S): RIEMERSMA, RUDOLPH A. PUBLISHER: AOCS PRESS, CHAMPAIGN, ILL., XP000921245 *
SHAH S ET AL: "Eicosapentaenoic acid (EPA) as an adjunct in the treatment of schizophrenia.", SCHIZOPHRENIA RESEARCH, vol. 29, no. 1-2, January 1998 (1998-01-01), Ninth Biennial Winter Workshop on Schizophrenia;Davos, Switzerland; February 7-13, 1998, pages 158, XP000921338, ISSN: 0920-9964 *
VREUGDENHIL M ET AL: "Anticonvulsant properties of polyunsaturated fatty acids.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 22, no. 1-3, 1996, 26th Annual Meeting of the Society for Neuroscience;Washington, D.C., USA; November 16-21, 1996, pages 2106, XP000921389, ISSN: 0190-5295 *

Also Published As

Publication number Publication date
WO2000044360A2 (en) 2000-08-03
GB9901808D0 (en) 1999-03-17
AU3063800A (en) 2000-08-18

Similar Documents

Publication Publication Date Title
CA2360776A1 (en) Highly purified ethyl epa and other epa derivatives for psychiatric and neurological disorders
CA2409819A1 (en) Triazole derivatives
FR2710638B1 (en) Process for the preparation of isomers of high purity benzenedicarboxylic acids.
RU2002133098A (en) THERAPEUTIC COMBINATIONS OF FATTY ACIDS
RU2001121185A (en) High purity ethyl EPA and other derivatives of EPA for psychiatric and neurological disorders
BR9401482A (en) 1H-Indol-3-acetamide, pharmaceutical formulation, use of a compound and process for the preparation of 1h-indole-3-acetamide
DE60036290D1 (en) PYRAZOL DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF AND PESTICIDES CONTAINING THESE AS ACTIVE INGREDIENTS
WO1988009789A2 (en) 3-indolepyruvic acid derivatives and pharmaceutical use thereof
WO1998052549A3 (en) Use of fumaric acid derivatives
NO20071498L (en) Substituted acyl hydroxamic acids as well as methods for reducing the TNFα level
WO2003047577A3 (en) Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses
EP0664289A3 (en) Isoquinolines
WO2005097763A3 (en) 1,3,4-oxadiazol-2-ones as ppar delta
DOP2002000512A (en) SUCCINATE ACID SALTS OF 5,7,14-TRIAZATETRACICLO [10.3.1.0² ¹¹.04,9] HEXADECA-2 (11), 3,5,7,9-PENTAENE AND PHARMACEUTICAL COMPOSITIONS OF THE SAME
EP0675100A3 (en) Preparation of alpha-beta-unsaturated c3-c6 carboxylic acids
MXPA05012391A (en) Treatment of psychotic and depressive disorders.
WO2003041646A3 (en) L-dopa ethyl ester salts and uses thereof
AU3784197A (en) New isoquinoline derivatives
AU7425391A (en) Use of n-alkylated 1, 4-dihydropyridinedicarboxylic acid esters as medicaments, new compounds and processes for their preparation
WO2002100836A3 (en) Compounds, compositions and methods for modulating beta-amyloid production
WO2000044360A3 (en) Drugs for treatment of psychiatric and brain disorders
DE69428008D1 (en) Production process of 2,5-diarylamino-3,6-dihydroterephthalic acid dialkyl ester and the production of quinacridones from these esters as intermediates
DE69332947T2 (en) MEDICINAL PRODUCT CONTAINING 2- (3-BENZOYLPHENYL) -PROPIONIC ACID FOR USE AS AN ANALGETIC
DE69923838D1 (en) STEREOISOMERS OF PROPYL ISOPROPYL ACETAMIDE, PROCESS FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEREOF
DE3261625D1 (en) Tricyclic thiazolyl oxamic acids and derivatives, process for their production, and therapeutic agents containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase